Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Head and Neck Squamous Cell Carcinoma
NCT00507767Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2007
- Primary completion
- Feb 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Started Jul 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00507767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00507767.